Almirall, S.A. (ALM.MC)

8,50 -0,02 (-0,29%) Al cierre: 05:35PM CEST

Almirall, S.A.

Ronda General Mitre, 151
Barcelona 08022
Spain
34 93 291 30 00
https://www.almirall.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 1996

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Carlos Gallardo Piqué	CEO, President, Member of Management Board & Chairman of the Board	50k	N/A	1972
Mr. Michael McClellan	CFO & Member of Management Board	N/A	N/A	1972
Mr. Eloi Crespo Cervera	Chief Industrial Operations Officer & Member of Management Board	N/A	N/A	N/A
Mr. Esteve Conesa Panicot	Chief People & Culture Officer and Member of Management Board	N/A	N/A	N/A
Dr. Volker Koscielny	Chief Medical Officer & Member of Management Board	N/A	N/A	N/A
Dr. Karl Ziegelbauer	Chief Scientific Officer & Member of Management Board	N/A	N/A	N/A
Mr. Paolo Cionini	Chief Commercial Officer Europe & International and Member of Management Board	N/A	N/A	N/A
Ms. Isabel Cristina Gomes	Company Vice Secretary,Chief Legal Officer, General Counsel & Member of Management Board	N/A	N/A	N/A
Ms. Mercedes Diz Lopez	Chief Marketing Officer & Member of Management Board	N/A	N/A	N/A
Mr. Pablo Divasson del Fraile	Senior Director of Investor Relations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2015 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Gobierno corporativo

El ISS Governance QualityScore de Almirall, S.A., a día 1 de septiembre de 2024, es 2. Las puntuaciones base son Auditoría: 4; Tablero: 3; Derechos de los accionistas: 3; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.